RxDoctor Payments Data

Lenore Bonanno, PA

Medical · Stony Brook, NYNPI 1750554515

Payments from drug & device makers

$724in general payments, 2019–2025

Across 14 payments — averaging $51.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$196
  • Pharmaessentia USA Corporation$174
  • Janssen Scientific Affairs, LLC$115
  • Johnson & Johnson$65
  • Sanofi-aventis U.S. LLC$49
  • Kyowa Kirin, Inc.$29
  • plus $95 from 4 others

What the payments were for

  • Consulting fees$29040%
  • Food & beverage$36951%
  • Education$659%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$724 in reported general payments places this provider in the 60th percentile of 2,395 medical providers in New York.

See all medical providers in New York

Medicare billing

Part B allowed, 2024
$17,133
Medicare patients
52
Services billed
158

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PomalystPomalidomide45$1,085,636
Lenalidomide60$833,189
RevlimidLenalidomide47$812,613
ImbruvicaIbrutinib23$368,049
OnuregAzacitidine13$324,435
RezurockBelumosudil Mesylate16$272,199
JakafiRuxolitinib Phosphate14$217,943
Imatinib Mesylate26$151,458
EliquisApixaban35$20,401
XareltoRivaroxaban15$10,329
Voriconazole24$6,504
ValacyclovirValacyclovir Hcl113$5,290
Fluconazole32$2,887
Acyclovir47$773
Omeprazole22$367

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$25$812,61347 claims
Sanofi-aventis U.S. LLCRezurock$49$272,19916 claims
PfizerEliquis$196$20,40135 claims
Johnson & JohnsonXarelto$65$10,32915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,395 medical providers in New York.

Other medical in Stony Brook

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →